Meridian Bioscience Announces the Launch of a High-Sensitivity SARS-CoV-2 Nucleocapsid Antibody Pair for the Development of R...
July 13 2020 - 12:00PM
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of
diagnostic testing solutions and life science raw materials,
announced today that it has launched a high-sensitivity SARS-CoV-2
nucleocapsid antibody pair for the development of rapid COVID-19
antigen assays.
Since the emergence of COVID-19 in January,
Meridian has worked side-by-side with molecular diagnostic
companies with critical master mixes and enzymes for their COVID-19
molecular diagnostics tests. These tests are typically
ultra-sensitive and can diagnose early in the infection, but they
must be carried out by trained technicians in a laboratory,
delaying diagnosis. To meet the critical need for easier,
faster and cheaper screening assays, Meridian has launched a highly
sensitive and specific pair of monoclonal antibodies that are ideal
for developing reliable and sensitive rapid lateral flow antigen
assays for the detection of active COVID-19 infections.
“There are many highly sensitive molecular tests
available that can diagnose an infection early, but they require
processing in a laboratory and take time to report a result.
We now provide an antibody pair that can be used to create fast,
point-of-care assays, capable of delivering results in minutes
rather than hours,” commented Lourdes Weltzien, Ph.D., Executive
Vice President, Life Science. “Although a negative result
does not rule out an infection, antigen tests can be a first-line
screen to help determine if people are infectious, allowing much
faster response to potential outbreaks.”
Dr. Todd Howren, Vice President, Global Sales -
Life Science, added, “Since the start of this pandemic, the world
has been on the defensive, reacting to the outbreak. With the
launch of this antibody pair that can detect as low as 3ng/mL of
nucleocapsid in a patient sample and does not cross react with
other coronaviruses (except SARS 2003), there is potential to
create COVID-19 tests that can be carried out at a point-of-care
setting in local communities allowing for more rigorous
control.”
Meridian is committed to suppling innovative
solutions to the diagnostic industry during times of a pandemic
health crisis. For more information on partnering with
Meridian Bioscience, please visit meridianlifescience.com or email
Lourdes.Weltzien@meridianlifescience.com.
About Meridian Bioscience,
Inc.Meridian is a fully integrated life science company
that develops, manufactures, markets and distributes a broad range
of innovative diagnostic products. We are dedicated to developing
and delivering better solutions that give answers with speed,
accuracy and simplicity that are redefining the possibilities of
life from discovery to diagnosis. Through discovery and
development, we provide critical life science raw materials used in
immunological and molecular tests for human, animal, plant, and
environmental applications. Through diagnosis, we provide
diagnostic solutions in areas including gastrointestinal and upper
respiratory infections and blood lead level testing. We build
relationships and provide solutions to hospitals, reference
laboratories, research centers, veterinary testing centers,
physician offices, diagnostics manufacturers, and biotech companies
in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ
Global Select Market, symbol VIVO. Meridian’s website address is
www.meridianbioscience.com.
Contact:Charlie WoodVice President – Investor
RelationsMeridian Bioscience, Inc.Phone: +1
513.271.3700Email: mbi@meridianbioscience.com
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Jul 2023 to Jul 2024